Clinical Trial Update: Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating whether HER2-amplified circulating tumor cells can identify metastatic breast cancer patients with HER2-negative primary tumors who may…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Kadcyla (ado-trastuzumab emtansine)

Snippet

Sponsor: Institut Curie | Conditions: Metastatic Breast Cancer, HER2 Negative Primary Tumor | Phase 2 | Status: COMPLETED